ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2007
Immunosuppressive agents in multiple sclerosis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Network pharmacology-based analysis of the role of tacrolimus in liver transplantation.Saudi journal of biological sciences · 2021Article
- Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease.Molecular pharmaceutics · 2019Article
- [Rapamycin alleviates inflammation by up-regulating TGF-β/Smad signaling in a mouse model of autoimmune encephalomyelitis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway.Neurochemical research · 2017Article
- Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.Annals of clinical and translational neurology · 2017Article
- A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Role of immunosuppressive therapy for the treatment of multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.The pharmacogenomics journal · 2012Review
- A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Discovery medicine · 2011Review
- Successful management of a neurology infusion practice.International journal of MS care · 2011Article
- Animal models of multiple sclerosis--potentials and limitations.Progress in neurobiology · 2010Review
- Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.Adolescent health, medicine and therapeutics · 2010Review
- [Intravenous immunoglobulins in multiple sclerosis. An update].Der Nervenarzt · 2009Review
- Neurodegenerative disorders and nanoformulated drug development.Nanomedicine (London, England) · 2009Review
- Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis.Arthritis research & therapy · 2008Article
- Disease-modifying therapies in multiple sclerosis in Latin America.Multiple sclerosis journal - experimental, translational and clinicalReview
- Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressive agents have been used in multiple sclerosis (MS) for decades. The approval of several immunomodulatory agents against MS beginning in the 1990s, whose putative mechanisms of action appeared "more MS-specific," curtailed the importance of immunosuppressants, which made them treatment options of second choice. However, with the recent approval of mitoxantrone for treatment of patients with active forms of relapsing-remitting or secondary progressive MS and with a number of oral immunosuppressive agents being assessed in phase II and III clinical trials, a "renaissance" of this type of agents is currently occurring. This review provides an outline of the most important clinical studies and discusses relevant side effects of the major immunosuppressants (i.e., mitoxantrone, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, cladribine, and sirolimus/temsirolimus). The current knowledge of the putative mechanisms of action of these compounds is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.